While drug makers are trying to improve the ethnic and racial mix of clinical trial populations, one of the biggest barriers is trust – especially among communities that continue to feel the legacy of mistreatment by the medical system. As Novavax, Inc. worked to improve the diversity of the Phase III PREVENT-19 trial of its COVID-19 vaccine NVX-CoV2373, focusing on trust was one of the ways it successfully bolstered enrollment by Native American participants.
Citeline Award Nominee
Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this urgent area. Watch for additional interviews to come, and follow the
The company enrolled more than 30,000 adults and adolescents into the PREVENT-19 study, which showed 90.4% overall efficacy and 100% efficacy at preventing moderate and severe disease and will be the basis of the regulatory filing. (Also see "Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets" - Scrip, 6 August, 2021.) The trial was run at 148 sites, most of them in the US, with a handful in Mexico
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
